Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 36

1.

Role of osteopontin as a predictive biomarker for anti-EGFR therapy in triple-negative breast cancer.

Anborgh PH, Lee DJ, Stam PF, Tuck AB, Chambers AF.

Expert Opin Ther Targets. 2018 Aug;22(8):727-734. doi: 10.1080/14728222.2018.1502272. Epub 2018 Jul 26.

PMID:
30025479
2.

Role of plasma osteopontin as a biomarker in locally advanced breast cancer.

Anborgh PH, Caria LB, Chambers AF, Tuck AB, Stitt LW, Brackstone M.

Am J Transl Res. 2015 Apr 15;7(4):723-32. eCollection 2015.

3.

Assessment of osteopontin in early breast cancer: correlative study in a randomised clinical trial.

Bramwell VH, Tuck AB, Chapman JA, Anborgh PH, Postenka CO, Al-Katib W, Shepherd LE, Han L, Wilson CF, Pritchard KI, Pollak MN, Chambers AF.

Breast Cancer Res. 2014 Jan 22;16(1):R8. doi: 10.1186/bcr3600.

4.

Plasma osteopontin as a biomarker of prostate cancer aggression: relationship to risk category and treatment response.

Thoms JW, Dal Pra A, Anborgh PH, Christensen E, Fleshner N, Menard C, Chadwick K, Milosevic M, Catton C, Pintilie M, Chambers AF, Bristow RG.

Br J Cancer. 2012 Aug 21;107(5):840-6. doi: 10.1038/bjc.2012.345. Epub 2012 Aug 7.

5.

Pre- and post-translational regulation of osteopontin in cancer.

Anborgh PH, Mutrie JC, Tuck AB, Chambers AF.

J Cell Commun Signal. 2011 Jun;5(2):111-22. doi: 10.1007/s12079-011-0130-6. Epub 2011 Apr 26.

6.

Role of the metastasis-promoting protein osteopontin in the tumour microenvironment.

Anborgh PH, Mutrie JC, Tuck AB, Chambers AF.

J Cell Mol Med. 2010 Aug;14(8):2037-44. doi: 10.1111/j.1582-4934.2010.01115.x. Epub 2010 Jul 1. Review.

7.

Rapid and direct transport of cell surface APP to the lysosome defines a novel selective pathway.

Lorenzen A, Samosh J, Vandewark K, Anborgh PH, Seah C, Magalhaes AC, Cregan SP, Ferguson SS, Pasternak SH.

Mol Brain. 2010 Apr 21;3:11. doi: 10.1186/1756-6606-3-11.

8.

New dual monoclonal ELISA for measuring plasma osteopontin as a biomarker associated with survival in prostate cancer: clinical validation and comparison of multiple ELISAs.

Anborgh PH, Wilson SM, Tuck AB, Winquist E, Schmidt N, Hart R, Kon S, Maeda M, Uede T, Stitt LW, Chambers AF.

Clin Chem. 2009 May;55(5):895-903. doi: 10.1373/clinchem.2008.117465. Epub 2009 Mar 26.

9.

Inhibition of metabotropic glutamate receptor signaling by the huntingtin-binding protein optineurin.

Anborgh PH, Godin C, Pampillo M, Dhami GK, Dale LB, Cregan SP, Truant R, Ferguson SS.

J Biol Chem. 2005 Oct 14;280(41):34840-8. Epub 2005 Aug 9.

10.

Effects of the antibiotic pulvomycin on the elongation factor Tu-dependent reactions. Comparison with other antibiotics.

Anborgh PH, Okamura S, Parmeggiani A.

Biochemistry. 2004 Dec 14;43(49):15550-6.

PMID:
15581367
11.

Ral and phospholipase D2-dependent pathway for constitutive metabotropic glutamate receptor endocytosis.

Bhattacharya M, Babwah AV, Godin C, Anborgh PH, Dale LB, Poulter MO, Ferguson SS.

J Neurosci. 2004 Oct 6;24(40):8752-61.

12.

G Protein-coupled receptor kinase 2 regulator of G protein signaling homology domain binds to both metabotropic glutamate receptor 1a and Galphaq to attenuate signaling.

Dhami GK, Dale LB, Anborgh PH, O'Connor-Halligan KE, Sterne-Marr R, Ferguson SS.

J Biol Chem. 2004 Apr 16;279(16):16614-20. Epub 2004 Feb 4.

13.

Beta-arrestins regulate a Ral-GDS Ral effector pathway that mediates cytoskeletal reorganization.

Bhattacharya M, Anborgh PH, Babwah AV, Dale LB, Dobransky T, Benovic JL, Feldman RD, Verdi JM, Rylett RJ, Ferguson SS.

Nat Cell Biol. 2002 Aug;4(8):547-55.

PMID:
12105416
14.

Phosphorylation-independent regulation of metabotropic glutamate receptor signaling by G protein-coupled receptor kinase 2.

Dhami GK, Anborgh PH, Dale LB, Sterne-Marr R, Ferguson SS.

J Biol Chem. 2002 Jul 12;277(28):25266-72. Epub 2002 May 6.

15.
16.

Rab5 association with the angiotensin II type 1A receptor promotes Rab5 GTP binding and vesicular fusion.

Seachrist JL, Laporte SA, Dale LB, Babwah AV, Caron MG, Anborgh PH, Ferguson SS.

J Biol Chem. 2002 Jan 4;277(1):679-85. Epub 2001 Oct 26.

17.
18.

G protein-coupled receptor kinase-mediated desensitization of metabotropic glutamate receptor 1A protects against cell death.

Dale LB, Bhattacharya M, Anborgh PH, Murdoch B, Bhatia M, Nakanishi S, Ferguson SS.

J Biol Chem. 2000 Dec 8;275(49):38213-20.

19.
20.

Ras-specific exchange factor GRF: oligomerization through its Dbl homology domain and calcium-dependent activation of Raf.

Anborgh PH, Qian X, Papageorge AG, Vass WC, DeClue JE, Lowy DR.

Mol Cell Biol. 1999 Jul;19(7):4611-22.

21.

Cellular trafficking of G protein-coupled receptor/beta-arrestin endocytic complexes.

Zhang J, Barak LS, Anborgh PH, Laporte SA, Caron MG, Ferguson SS.

J Biol Chem. 1999 Apr 16;274(16):10999-1006.

23.

Functional role of the noncatalytic domains of elongation factor Tu in the interactions with ligands.

Cetin R, Anborgh PH, Cool RH, Parmeggiani A.

Biochemistry. 1998 Jan 13;37(2):486-95.

PMID:
9425069
24.

N terminus of Sos1 Ras exchange factor: critical roles for the Dbl and pleckstrin homology domains.

Qian X, Vass WC, Papageorge AG, Anborgh PH, Lowy DR.

Mol Cell Biol. 1998 Feb;18(2):771-8.

25.

Enacyloxin IIa, an inhibitor of protein biosynthesis that acts on elongation factor Tu and the ribosome.

Cetin R, Krab IM, Anborgh PH, Cool RH, Watanabe T, Sugiyama T, Izaki K, Parmeggiani A.

EMBO J. 1996 May 15;15(10):2604-11.

26.

Antibiotic resistance mechanisms of mutant EF-Tu species in Escherichia coli.

Kraal B, Zeef LA, Mesters JR, Boon K, Vorstenbosch EL, Bosch L, Anborgh PH, Parmeggiani A, Hilgenfeld R.

Biochem Cell Biol. 1995 Nov-Dec;73(11-12):1167-77. Review.

PMID:
8722034
27.

Pulvomycin-resistant mutants of E.coli elongation factor Tu.

Zeef LA, Bosch L, Anborgh PH, Cetin R, Parmeggiani A, Hilgenfeld R.

EMBO J. 1994 Nov 1;13(21):5113-20.

28.
29.
30.

Site-directed mutagenesis of elongation factor Tu. The functional and structural role of residue Cys81.

Anborgh PH, Parmeggiani A, Jonák J.

Eur J Biochem. 1992 Sep 1;208(2):251-7.

31.
32.

Elongation factor Tu: a molecular switch in protein biosynthesis.

Weijland A, Harmark K, Cool RH, Anborgh PH, Parmeggiani A.

Mol Microbiol. 1992 Mar;6(6):683-8. Review.

PMID:
1573997
33.

Kirromycin-induced modifications facilitate the separation of EF-Tu species and reveal intermolecular interactions.

Anborgh PH, Swart GW, Parmeggiani A.

FEBS Lett. 1991 Nov 4;292(1-2):232-6. Erratum in: FEBS Lett 1991 Dec 16;295(1-3):232.

34.

Structure-function relationships of elongation factor Tu as studied by mutagenesis.

Anborgh PH, Cool RH, Gümüsel F, Harmark K, Jacquet E, Weijland A, Mistou MY, Parmeggiani A.

Biochimie. 1991 Jul-Aug;73(7-8):1051-9.

PMID:
1742350
35.
36.

Mutagenesis of the NH2-terminal domain of elongation factor Tu.

Gümüşel F, Cool RH, Weijland A, Anborgh PH, Parmeggiani A.

Biochim Biophys Acta. 1990 Aug 27;1050(1-3):215-21.

PMID:
2119812

Supplemental Content

Loading ...
Support Center